While our findings suggest that JNK plays an active role in promoting survival of resistant HER2+ breast cancer cells, our findings in Fig 2 suggest that JNK is not able to act in conjunction with lapatinib to further impair tumorigenesis. The gene discussed is ERBB2; the disease is breast carcinoma.